MedTrace Logo

Treatment Planning for ABA Employing Auxiliary Tools V2+ (TREAAT2+)

NCT06204536 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-11-22

No results posted yet for this study

Summary

Technology enhancement in Applied Behavior Analysis (ABA) treatment planning may increase confidence, efficiency, consistency, and satisfaction for Board Certified Behavior Analysts (BCBAs) which, in turn, can provide for better clinical outcomes for patients on the autism spectrum. To this end, the investigators will examine the use of \>3 technology-based tools that will be implemented in the BCBAs' clinical workflow to aid with treatment planning. The study will initially involve two aims that are non-interventional (these processes will occur in the background and will have no impact on any cohorts), followed by an interventional aim that includes two arms (i.e., two BCBA cohorts). BCBAs within both arms will observe and practice the standard of care for ABA, and thus patient care will not be impacted. The outcome measures are primarily focused on the BCBAs as follows: Arm 1: An experimental group (BCBA Tech cohort) will receive the full tech package (TREAAT2+) from the start. Arm 2: The control group (BCBA non-Tech cohort) will not have access to any tools from the tech package for the first 6 months. In the subsequent 18 months, they will receive one tool every 6 months until gaining access to the entire tech package.

Conditions

Interventions

OTHER

Tech-enabled ABA treatment planning

The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.

Sponsors & Collaborators

  • Montera Health Texas LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2027-06-30
Completion
2027-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204536 on ClinicalTrials.gov